Research
Hormonal
Tirzepatide achieved MASH resolution with no worsening of fibrosis in a significantly higher percentage of patients than placebo.
Tirzepatide may be a promising treatment option for patients with MASH, potentially improving liver health.
StrongSupportsmedium confidence
Results from SYNERGY-NASH...have shown that tirzepatide achieved MASH resolution with no worsening of fibrosis in a significantly higher percentage of patients than placebo.
Why this rating
Based on results from a phase 2 clinical trial.
Source
Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives
Stefano Fiorucci et al. · Expert Opinion on Investigational Drugs · 2025
DOI 10.1080/13543784.2025.2546812
rctCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →